394 related articles for article (PubMed ID: 21879445)
21. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design.
Hodawadekar SC; Marmorstein R
Oncogene; 2007 Aug; 26(37):5528-40. PubMed ID: 17694092
[TBL] [Abstract][Full Text] [Related]
22. K-acetylation and its enzymes: overview and new developments.
Aka JA; Kim GW; Yang XJ
Handb Exp Pharmacol; 2011; 206():1-12. PubMed ID: 21879443
[TBL] [Abstract][Full Text] [Related]
23. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylases and cancer.
Glozak MA; Seto E
Oncogene; 2007 Aug; 26(37):5420-32. PubMed ID: 17694083
[TBL] [Abstract][Full Text] [Related]
25. NMR profiling of histone deacetylase and acetyl-transferase activities in real time.
Dose A; Liokatis S; Theillet FX; Selenko P; Schwarzer D
ACS Chem Biol; 2011 May; 6(5):419-24. PubMed ID: 21302972
[TBL] [Abstract][Full Text] [Related]
26. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
[TBL] [Abstract][Full Text] [Related]
27. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors--a new tool to treat cancer.
Somech R; Izraeli S; J Simon A
Cancer Treat Rev; 2004 Aug; 30(5):461-72. PubMed ID: 15245778
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylases--an important class of cellular regulators with a variety of functions.
Hildmann C; Riester D; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
[TBL] [Abstract][Full Text] [Related]
31. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
33. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
34. Deacetylation of Transcription Factors in Carcinogenesis.
Halasa M; Adamczuk K; Adamczuk G; Afshan S; Stepulak A; Cybulski M; Wawruszak A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769241
[TBL] [Abstract][Full Text] [Related]
35. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
36. Acetylation of nuclear receptors in cellular growth and apoptosis.
Fu M; Wang C; Zhang X; Pestell RG
Biochem Pharmacol; 2004 Sep; 68(6):1199-208. PubMed ID: 15313417
[TBL] [Abstract][Full Text] [Related]
37. Important roles of reversible acetylation in the function of hematopoietic transcription factors.
Huo X; Zhang J
J Cell Mol Med; 2005; 9(1):103-12. PubMed ID: 15784168
[TBL] [Abstract][Full Text] [Related]
38. Histone acetyl transferases as emerging drug targets.
Dekker FJ; Haisma HJ
Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
[TBL] [Abstract][Full Text] [Related]
39. Acetylation in cardiovascular diseases: Molecular mechanisms and clinical implications.
Yang M; Zhang Y; Ren J
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165836. PubMed ID: 32413386
[TBL] [Abstract][Full Text] [Related]
40. Cancers with wrong HATs: the impact of acetylation.
Di Cerbo V; Schneider R
Brief Funct Genomics; 2013 May; 12(3):231-43. PubMed ID: 23325510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
